ReviewJournal for immunotherapy of cancer2020
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.
Review in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.Cancer immunology, immunotherapy : CII · 2022Pooled it
- Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.Targeted oncology · 2021Pooled it
- Discovery of novel disulfide-containing PD-1/PD-L1 inhibitor with in vivo influenza therapeutic efficacy.Scientific reports · 2025Article
- Contrasting roles of PSGL-1 and PD-1 in regulating T-cell exhaustion and function during chronic viral infection.Journal of virology · 2025Article
- Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Article
- Article
- Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis.Viruses · 2024Article
- Meeting the Challenge of Controlling Viral Immunopathology.International journal of molecular sciences · 2024Review
- Hypocortisolemic ASIA: a vaccine- and chronic infection-induced syndrome behind the origin of long COVID and myalgic encephalomyelitis.Frontiers in immunology · 2024Review
- Predicting survival in patients with SARS-CoV-2 based on cytokines and soluble immune checkpoint regulators.Frontiers in cellular and infection microbiology · 2024Article
- Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature.Microorganisms · 2023Review
- Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach.Current pharmaceutical biotechnology · 2023Review
- Low-intensity focused ultrasound targeted microbubble destruction reduces tumor blood supply and sensitizes anti-PD-L1 immunotherapy.Frontiers in bioengineering and biotechnology · 2023Article
- Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2022Review
- Narrative Review: Addressing Covid-19 Vaccine Concerns in Special and Vulnerable Populations.Hospital pharmacy · 2022Article
- COVID-19 Vaccines and Immunosuppressed Patients With Cancer: Critical Considerations.Clinical journal of oncology nursing · 2022Article
- SARS-CoV-2 triggering autoimmune diseases.Cytokine · 2022Review
- Article
- COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.Frontiers in immunology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.